profit from every $100 of sales.
$0$100
Milestone Pharmaceuticals
$0.66+0.00% today
-65.3% in 1 year
1-year low $0.641-year high $2.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Milestone Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $5.00 million in 2022 to $1.55 million in 2025, with -$63.1 million of profit last year.
SalesProfit
Milestone Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Milestone Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Milestone Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 1 | 0 | 2 | |
| – | – | – | – | |
| -60 | -61 | -42 | -62 | |
| -58 | -57 | -38 | -59 | |
| -58 | -60 | -42 | -63 | |
| -1.38 | -1.39 | -0.67 | -0.75 | |
| – | – | – | – | |
| -1,192.8% | -6,109.8% | – | -4,019.4% | |
| -1,167.8% | -5,968.5% | – | -4,078.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 74 | 75 | 75 | 114 |
| Cash | 8 | 14 | 25 | 73 |
| Total debt | 2 | 52 | 55 | 58 |
| Total liabilities | 8 | 58 | 62 | 72 |
| 66 | 17 | 13 | 42 | |
| 42 | 43 | 62 | 84 | |
| -67.0% | -65.8% | -44.1% | -46.7% | |
| -88.0% | -355.9% | -315.8% | -151.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52 | -46 | -29 | -49 | |
| 0 | 0 | 0 | 0 | |
| -53 | -47 | -29 | -49 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 10 | 6 | 7 |
Valuation
- –
- –
- –
- 5.4×
- 53.3×
- –
- –
- -59.9%
- -76.5%
- 0.0%
Profitability
- 94.7%
- -4,019.4%
- -4,078.8%
- -3,536.8%
- -37.6%
- -66.8%
- -339.4%
- -35.3%
- -37.9%
- 928.4%
Growth
- −32.4%
- –
- −70.8%
- –
- +19.0%
Financial health
- -0.2×
- 3.81
- 70.9%
- -9.3×
- 9.18
- 9.09
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 958
Bottom 3%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $7.33
- Range
- $6.00 – $8.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.20 | 0.06 | −433.3% |
| Mar 20, 2026 | -0.16 | -0.18 | +11.1% |
| Nov 12, 2025 | -0.12 | -0.17 | +29.4% |
| Aug 12, 2025 | -0.20 | -0.18 | −11.1% |
| May 14, 2025 | -0.31 | -0.19 | −63.2% |
| Mar 13, 2025 | -0.19 | -0.15 | −26.7% |
| Nov 12, 2024 | -0.14 | -0.16 | +12.5% |
| Aug 8, 2024 | -0.14 | -0.19 | +26.3% |
News
MP Materials Clears GM Magnet Milestone, Targets Apple as Next CustomerYahoo Finance · Nov 11, 2026The S&P 500 Is Chasing a Milestone That's Only Been Hit 9 Times Since 1926. Here’s What History Says Comes Next.Yahoo Finance · Nov 1, 2026Elon Musk Became the First Person Ever Confirmed With a Net Worth Above $1 Trillion in June 2026. Here's Why That Milestone Still Matters for Tesla and SpaceX Shareholders.Yahoo Finance · Oct 25, 2026Investing, not homeownership, is the No. 1 milestone that makes Gen Z renters feel successfulMarketWatch · Oct 17, 2026Anthropic Just Became the First Company in History To Reach This Milestone. Here's What It Means for AI StocksYahoo Finance · Oct 15, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
22No pass
Philip Fisher
51No pass
Peter Lynch
2No pass
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
48No pass
Questions about Milestone Pharmaceuticals
Is Milestone Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Milestone Pharmaceuticals AI analysis
What does Milestone Pharmaceuticals do?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is in Biotechnology.
Does Milestone Pharmaceuticals pay a dividend?
No. Milestone Pharmaceuticals does not pay a dividend at the moment.
Is Milestone Pharmaceuticals stock halal?
No. Milestone Pharmaceuticals does not pass our halal screen: its debt is 71% of its market value, at or above the 33% limit. How we check
How has Milestone Pharmaceuticals stock done over the past year?
Down 65.3% over the past twelve months, to $0.66. It traded between $0.64 and $2.95 and is 77.6% below its high.
Who are Milestone Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Milestone Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.